S)-2,4-Di-tert-butyl-6-[(4S,5R)-3-iso­propyl-4-methyl-5-phenyloxazolidin-2-yl]phenol
[Figure 2]
[Figure 2]

disable zoom     view article
Figure 2 . The enhanced Jmol figure of the title compound. This is the second in a series of three Jmol figures intended to illustrate some versatility of the program. In this Jmol, all inter­active features are defined by using the graphical inter­face. In addition, the view associated with each script is changed to highlight the script contents. Some script artifacts occur and can only be remedied by hand-editing the scripts.





Highlight N3 substituent
Highlight C18 and substituent
Highlight C20 and substituent
Highlight none











This is the second in a series of three Jmol figures intended to illustrate some versatility of the program. In this Jmol, all interactive features are defined by using the graphical interface. In addition, the view associated with each script is changed to highlight the script contents. Some script artifacts occur and can only be remedied by hand-editing the scripts.

Figure 2 . The enhanced Jmol figure of the title compound. This is the second in a series of three Jmol figures intended to illustrate some versatility of the program. In this Jmol, all inter­active features are defined by using the graphical inter­face. In addition, the view associated with each script is changed to highlight the script contents. Some script artifacts occur and can only be remedied by hand-editing the scripts.

Journal logo CRYSTALLOGRAPHIC
COMMUNICATIONS
ISSN: 2056-9890
Volume 66| Part 4| March 2010| Pages o900-o901
doi:10.1107/S1600536810009074
Follow Acta Cryst. E
Sign up for e-alerts
E-alerts
Follow Acta Cryst. on Twitter
Twitter
Follow us on facebook
Facebook
Sign up for RSS feeds
RSS